SG&A Efficiency Analysis: Comparing Johnson & Johnson and Viatris Inc.

SG&A Trends: Johnson & Johnson vs. Viatris Inc.

__timestampJohnson & JohnsonViatris Inc.
Wednesday, January 1, 2014219540000001499100000
Thursday, January 1, 2015212030000001923500000
Friday, January 1, 2016199450000002351400000
Sunday, January 1, 2017214200000002564000000
Monday, January 1, 2018225400000002397300000
Tuesday, January 1, 2019221780000002503400000
Wednesday, January 1, 2020220840000003344600000
Friday, January 1, 2021201180000004529200000
Saturday, January 1, 2022190460000004179100000
Sunday, January 1, 2023201120000004650100000
Loading chart...

Unleashing the power of data

SG&A Efficiency: A Tale of Two Giants

In the ever-evolving pharmaceutical landscape, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Johnson & Johnson and Viatris Inc. have showcased contrasting trends in their SG&A expenditures. From 2014 to 2023, Johnson & Johnson's SG&A expenses have seen a modest decline of approximately 13%, reflecting a strategic tightening of operational costs. In contrast, Viatris Inc. has experienced a significant surge, with expenses tripling over the same period. This divergence highlights Johnson & Johnson's focus on cost efficiency, while Viatris Inc. appears to be investing heavily in growth and expansion. As the industry faces increasing pressure to innovate and reduce costs, these trends offer valuable insights into the strategic priorities of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025